Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival
    Journal Article

    Ujiie, H.; Kadota, K.; Chaft, J. E.; Buitrago, D.; Sima, C. S.; Lee, M. C.; Huang, J.; Travis, W. D.; Rizk, N. P.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • COMMAND: A phase 2 randomized, double-blind, study of defactinib (VS-6063) as maintenance therapy in malignant pleural mesothelioma
    Meeting Abstract

    Kindler, H. L.; Fennell, D. A.; Baas, P.; Krug, L. M.; Zauderer, M. G.; Nowak, A. K.; Gralla, R. J.; Nakano, T.; Joseney-Antoine, M.; Poli, A.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Occult primary non-small cell lung cancer with mediastinal lymph node involvement
    Meeting Abstract

    Romesser, P. B.; Rimner, A.; Foster, A.; Chaft, J. E.; Huang, J.; Jones, D. R.; Wu, A. J.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Basaloid squamous cell cancers arising from the lung: Next generation sequencing reveals PTCH1 mutations in the hedgehog pathway
    Meeting Abstract

    Li, B. T.; Rekhtman, N.; Won, H.; Arcila, M. E.; Rudin, C. M.; Kris, M. G.; Berger, M.; Paik, P.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of VS-5584, a PI3K/mTOR inhibitor, administered with VS-6063, a focal adhesion kinase inhibitor, in mesothelioma
    Meeting Abstract

    Banerji, U.; Fennell, D. A.; Kindler, H. L.; Zauderer, M. G.; Keegan, M.; Horobin, J.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Phase 2 trial of bortezomib in KRAS G12D mutant lung cancers
    Meeting Abstract

    Riely, G. J.; Litvak, A.; Rekhtman, N.; Pietanza, M. C.; Chaft, J. E.; Woo, K.; Paik, P.; Miller, V.; Kris, M. G.; Rodriguez, K.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Prognostic impact of EGFR and KRAS mutations in patients with lung adenocarcinoma treated with definitive radiation therapy
    Meeting Abstract

    Oro, F.; Sonnick, M.; Wang, H.; Zakowski, M.; Wu, A. J.; Chaft, J. E.; Paik, P.; Tsang, M.; Hsu, M.; Rosenzweig, K.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Clinical response to entrectinib in a patient with NTRK1-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Farago, A. F.; Patel, M.; Bauer, T.; Liu, S. V.; Drilon, A.; Wheler, J.; Ou, S. H.; Jackman, D. M.; Costa, D. B.; Multani, P.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • BAP1 inactivation in mesothelioma is highly prevalent
    Meeting Abstract

    Zauderer, M.; Cercek, A.; Rimner, A.; Rusch, V.; Adusumilli, P. S.; Nash, G. M.; Moreira, A.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF) pathway deregulated squamous NSCLC or MPM
    Meeting Abstract

    Garrido, P.; Delgado, I.; Felip, E.; Domine, M.; Paik, P.; Trigo, J.; Schellens, J.; Gadgeel, S.; Kindler, H. L.; Lara, P. Jr; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save